SynthesisEndocrine2026
Endocrine toxicities in immune checkpoint inhibitors and tyrosine kinase inhibitors combined treatment: from clinical trials to real-life practice.
Synthesis in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combination therapies with immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) have revolutionized the landscape of cancer treatment, improving the quality of life and overall survival of patients. A deep knowledge of the side effects of ICIs and TKIs combination therapy is mandatory to ensure patient compliance and improve clinical outcomes. Both ICIs and TKIs may cause endocrinopathies such as thyroid dysfunction, adrenal insufficiency, hypophysitis, and diabetes mellitus. To avoid life-threatening conditions and improve patient’s compliance and outcomes, an early diagnosis of endocrine toxicity should be achieved and a multidisciplinary approach involving both endocrinologists and oncologists may be beneficial. This review specifically examines the endocrine adverse events reported in the clinical trials of ICI plus TKI combined treatment, their underlying mechanisms, and practical management guidelines.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.